Phase II Study of Denosumab to Define the Role of Bone Related Biomarkers in Breast Cancer Bone Metastasis

Trial Profile

Phase II Study of Denosumab to Define the Role of Bone Related Biomarkers in Breast Cancer Bone Metastasis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2017

At a glance

  • Drugs Denosumab (Primary)
  • Indications Bone metastases; Breast cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 13 Feb 2017 Status changed from active, no longer recruiting to recruiting.
    • 09 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Feb 2015 Planned primary completion date changed from 1 Nov 2019 to 1 Feb 2020 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top